Showing 1–9 of 20 results
-
AED3,500.00
The 24G Pharmacogenomics plus DNA Test is a cutting-edge genetic analysis that provides personalized insights into drug response and overall health. It examines pharmacogenomics, helping to predict how your body metabolizes medications, reducing adverse drug reactions and optimizing treatment plans. Additionally, it includes a comprehensive DNA test covering traits, wellness, and genetic predispositions. Key benefits include personalized medication guidance, enhanced treatment safety, and actionable health insights.
Sample Type : Saliva
Methodology : Illumina
TAT : 3-6 Weeks
-
AED3,300.00
ALK Fusion – FISH is a fluorescence in situ hybridization (FISH) test designed to detect ALK gene rearrangements in tumor samples, primarily for non-small cell lung cancer (NSCLC) patients. Key features include high sensitivity and specificity, FDA approval for clinical diagnostics, and direct visualization of ALK gene fusions at the cellular level.
-
AED3,250.00
The BCR/ABL – Quantitative test is a highly sensitive molecular diagnostic assay used to detect and quantify the BCR-ABL fusion gene, a key biomarker in chronic myeloid leukemia (CML) and some acute lymphoblastic leukemias (ALL). Utilizing real-time PCR technology, it provides precise measurement of BCR-ABL transcript levels, enabling accurate disease monitoring and treatment response assessment.
Sample Type : Whole Blood
Methodology : Real time PCR
TAT : 8-10 Days
-
AED1,150.00
Sample Type : Whole Blood
Methodology : Enzyme-immunoassay
TAT : 10 Days
-
AED750.00
Sample Type : Serum
Methodology : Spectrophotometry
TAT : 10 Days
-
AED2,820.00
The HER-2/NEU – FISH Test is a highly precise diagnostic tool used to detect HER-2 gene amplification in breast cancer and other malignancies. Utilizing Fluorescence In Situ Hybridization (FISH) technology, it provides accurate, reliable, and early detection of HER-2 status, which is crucial for determining targeted therapy eligibility, such as Herceptin (trastuzumab) treatment. This test offers higher sensitivity and specificity compared to immunohistochemistry (IHC), reducing false-positive or false-negative results. Its rapid turnaround time and clinically validated methodology make it a gold standard for personalized cancer treatment, ensuring optimal therapeutic decisions and improved patient outcomes.
-
AED4,000.00
The **Hereditary Cancer Gene Panel (57 ACMG Genes)** is a comprehensive genetic test designed to assess inherited cancer risk by analyzing 57 clinically significant genes recommended by the **American College of Medical Genetics (ACMG)**. This panel identifies mutations linked to various hereditary cancers, including **breast, ovarian, colorectal, prostate, and pancreatic cancers**, enabling early detection and personalized risk management. Key features include **next-generation sequencing (NGS) technology** for high accuracy, expert-reviewed results, and actionable insights for **preventive care and targeted treatment strategies**. Ideal for individuals with a family history of cancer, this test empowers proactive healthcare decisions, offering **lifelong benefits through early intervention and precision medicine**.
-
AED4,000.00
The **Hereditary Cancer Panel 57 ACMG 20 HBOC & 865 Literature-Reviewed Genes** is a comprehensive genetic test designed to assess hereditary cancer risk. It analyzes **57 key genes**, including the **ACMG 20** and **HBOC-related genes**, alongside **865 literature-reviewed genes**, ensuring a thorough evaluation of cancer predisposition. This panel covers a wide range of hereditary cancers, including **breast, ovarian, colorectal, and more**, providing **clinically actionable insights** for early detection and personalized risk management. Utilizing **advanced sequencing technology**, it delivers **high accuracy and reliability**, making it an essential tool for **patients, healthcare providers, and genetic counselors**. Its unique combination of **expert-curated genes and extensive literature review** enhances diagnostic precision, setting it apart as a **cutting-edge solution for hereditary cancer risk assessment**.
-
AED950.00
Sample Type : Serum
Methodology : Electrophoresis
TAT : 10 Days
